United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc - sulfamethoxazole (unii: je42381tnv) (sulfamethoxazole - unii:je42381tnv), trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - sulfamethoxazole 800 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of bactrim (sulfamethoxazole and trimethoprim) tablets and other antibacterial drugs, bactrim (sulfamethoxazole and trimethoprim) tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. urinary tract infections for the treatment of urinary tract infections due to susceptible strains of the following organisms: escherichia coli , klebsiella species, enterobacter species, morganella morganii , proteus mirabilis and proteus vulgaris . it is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination

Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - concentrate for solution for infusion - trimethoprim 80 mg/5ml sulfamethoxazole 400 mg/5ml - antibacterials for systemic use

Malta - English - Medicines Authority

ej busuttil ltd busuttil buildings, triq l-ghadam, central business district zone 1, birkirkara, cbd 1060, malta - concentrate for solution for infusion - trimethoprim 80 mg/5ml sulfamethoxazole 400 mg/5ml - antibacterials for systemic use

Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - trimethoprim, sulfamethoxazole - concentrate for solution for infusion - trimethoprim 80 mg sulfamethoxazole 400 mg - antibacterials for systemic use

Australia - English - Department of Health (Therapeutic Goods Administration)

echo therapeutics pty ltd - trimethoprim, quantity: 80 mg; sulfamethoxazole, quantity: 400 mg - injection, concentrated - excipient ingredients: ethanol absolute; water for injections; monoethanolamine; propylene glycol; sodium hydroxide - parenteral administration of bactrim is indicated where oral dosage is not desirable or practical, e.g. pre- and post-operative infections associated with surgery, trauma or gynaecology; septicaemia and other infections due to sensitive organisms such as typhoid and paratyphoid.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - sulfamethoxazole (unii: je42381tnv) (sulfamethoxazole - unii:je42381tnv), trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - sulfamethoxazole 800 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of bactrim (sulfamethoxazole and trimethoprim) tablets and other antibacterial drugs, bactrim (sulfamethoxazole and trimethoprim) tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. urinary tract infections: for the treatment of urinary tract infections due to susceptible strains of the following organisms: escherichia coli , klebsiella species, enterobacter species, morganella morganii , proteus mirabilis and proteus vulgaris . it is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combinat

Australia - English - Department of Health (Therapeutic Goods Administration)

echo therapeutics pty ltd - trimethoprim, quantity: 160 mg; sulfamethoxazole, quantity: 800 mg - tablet - excipient ingredients: magnesium stearate; povidone; sodium starch glycollate; docusate sodium - upper and lower respiratory tract infections, renal and urinary tract infections; genital tract infections; gastrointestinal tract infections; skin and wound infections; septicaemias and other infections caused by sensitive organisms.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - sulfamethoxazole,trimethoprim -

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - trimethoprim; sulfamethoxazole -

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

f. hoffmann-la roche ltd. - sulfamethoxazole, trimethoprim - tablets - 800mg+ 160mg